Ergogenic aids: an update on ephedra.

Area of Science:

• Pharmacology
• Herbal Medicine
• Public Health

Background:

• Ephedra, utilized in traditional Chinese medicine for millennia, gained popularity in Western medicine in the 20th century.
• Its amphetamine-like properties led to widespread use in weight loss and athletic performance supplements, despite limited scientific evidence.
• The Dietary Supplement Health and Education Act of 1994 reduced FDA oversight, increasing the availability of ephedra products.

Purpose of the Study:

• To review the historical use and adverse effects of ephedra-containing supplements.
• To examine the regulatory history and eventual ban of ephedra products by the FDA.
• To highlight the link between ephedra's sympathomimetic activity and associated health risks.

Main Methods:

• Literature review of historical medical texts and scientific publications.
• Analysis of adverse event reports associated with ephedra supplementation.
• Examination of regulatory actions taken by the US Food and Drug Administration (FDA).

Main Results:

• Ephedra's sympathomimetic activity is linked to significant adverse effects, including cardiovascular and central nervous system diseases.
• Increased availability post-1994 led to a rise in reported adverse events.
• Mounting evidence of harm prompted the FDA to ban ephedra supplements in April 2004.

Conclusions:

• Ephedra-containing supplements pose serious health risks due to their sympathomimetic properties.
• Regulatory oversight is crucial for ensuring the safety of dietary supplements.
• The FDA's ban underscores the importance of evidence-based safety assessments for herbal products.